ReviewCirculation research2023
Gut Microbiota and Microbial Metabolism in Early Risk of Cardiometabolic Disease.
Review in Circulation research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of Clear Aligners on the Oral Microbiome: A Systematic Review of Current Evidence.Clinical and experimental dental research · 2026Pooled it
- Review
- Gut microbiome signatures discriminate deep vein thrombosis through machine learning and metabolic analysis.Scientific reports · 2026Article
- Gut Microbiome-Hormone Interactions and Precision Fermentation in the Prevention of Early Cardiovascular Risk in Adolescents.International journal of molecular sciences · 2026Review
- Review
- Gut microbiota dysbiosis, circulating microbial genetic traces, and their role in gestational diabetes.World journal of diabetes · 2026Review
- Nasal Microbiota as a Potential Therapeutic Target for Allergic Rhinitis: An Emerging Perspective.Current pharmaceutical design · 2026Review
- Harnessing the gut microbiome for precision therapeutics in heart failure.Frontiers in pharmacology · 2026Review
- Duration-dependent gut microbiota disruption drives opposing effects on adipose thermogenesis in obese mice.Frontiers in microbiology · 2026Article
- The gut microbiome-cardiometabolic axis: insights into obesity, type 2 diabetes, and hypertension.Frontiers in endocrinology · 2026Review
- Exercise benefits in metabolism on cardiovascular disease.Frontiers in cardiovascular medicine · 2026Review
- Pathogenic Role of mTOR Signaling in Cardiometabolic Disease: Implications for Heart, Liver, and Kidney Dysfunction.Physiological research · 2025Review
- From Mechanisms to Diseases: The Succinate-GPR91 Axis in Cardiometabolic Diseases.Journal of cardiovascular translational research · 2025Review
- Associations of fecal and blood microbiota-related metabolites with gut microbiota and type 2 diabetes in HIV infection.AIDS (London, England) · 2025Article
- Roadmap for alleviating the manifestations of ageing in the cardiovascular system.Nature reviews. Cardiology · 2025Review
- The role of the gut microbiota and its metabolites: a new predictor in diabetes and its complications.European journal of medical research · 2025Review
- Article
- A Comprehensive Pilot Study to Elucidate the Distinct Gut Microbial Composition and Its Functional Significance in Cardio-Metabolic Disease.Biochemical genetics · 2025Article
- Investigating the gut bacteria structure and function of hibernating bats through 16S rRNA high-throughput sequencing and culturomics.mSystems · 2025Article
- Proteomics and phosphoproteomics of freshwater mollusk carcasses reveal novel insights as potential food source.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Cardiometabolic disease comprises cardiovascular and metabolic dysfunction and underlies the leading causes of morbidity and mortality, both within the United States and worldwide. Commensal microbiota are implicated in the development of cardiometabolic disease. Evidence suggests that the microbiome is relatively variable during infancy and early childhood, becoming more fixed in later childhood and adulthood. Effects of microbiota, both during early development, and in later life, may induce changes in host metabolism that modulate risk mechanisms and predispose toward the development of cardiometabolic disease. In this review, we summarize the factors that influence gut microbiome composition and function during early life and explore how changes in microbiota and microbial metabolism influence host metabolism and cardiometabolic risk throughout life. We highlight limitations in current methodology and approaches and outline state-of-the-art advances, which are improving research and building toward refined diagnosis and treatment options in microbiome-targeted therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.